• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Chewable Pimobendan Tablet Matches Commercial Formulation in Beagle Dog Study

by
November 9, 2026
in Biology, Health
Reading Time: 2 mins read
0
Chewable Pimobendan Tablet Matches Commercial Formulation in Beagle Dog Study

Chewable Pimobendan Tablet Matches Commercial Formulation in Beagle Dog Study

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A newly developed pimobendan chewable tablet formulation demonstrated dissolution behavior and pharmacokinetic characteristics comparable to a commercially available formulation in beagle dogs, according to a study published in BMC Veterinary Research.

Pimobendan is an important cardiovascular drug widely used for the long-term management of cardiac diseases in dogs, and chewable tablets have been designed to facilitate oral administration. Because systematic investigations into the formulation development, pharmaceutical properties, stability, and in vivo pharmacokinetic behavior of such chewable tablets have remained limited, researchers aimed to develop and systematically assess a new formulation alongside an existing commercial counterpart.

Pharmaceutical characterization demonstrated that the newly developed chewable tablets met satisfactory standards across essential physical and chemical criteria. The tablets showed satisfactory quality in appearance, weight uniformity, content uniformity, mechanical properties, and moisture content.

In in vitro dissolution testing, the experimental chewable tablets produced a dissolution profile comparable to that of the commercially available product. Specifically, more than 80% of the pimobendan active ingredient was released within 30 minutes.

Stability evaluations revealed that the tablets maintained satisfactory quality when kept under accelerated and long-term storage conditions. However, exposure to light resulted in decreased drug content and reduced 30-minute cumulative performance, demonstrating the specific necessity for light-protective storage.

Following oral administration in beagle dogs, the developed tablets demonstrated rapid absorption and produced in vivo pharmacokinetic profiles comparable to the commercial formulation. The researchers detected no significant differences between the two formulations across major pharmacokinetic parameters, including Cmax, Tmax, Tlast, T1/2, AUC0–∞, Vz/F, CL/F, and MRT0–∞.

The study authors concluded that the formulation was successfully developed with satisfactory pharmaceutical properties and stability, offering useful insights for the preparation and testing of veterinary chewable tablets and representing a potential oral formulation for pimobendan administration in dogs.

Subject of Research: Pharmaceutical development and comparative pharmacokinetic evaluation of pimobendan chewable tablets in beagle dogs

Article Title: Development of pimobendan chewable tablets: pharmaceutical characterization and comparative pharmacokinetic evaluation in beagle dogs

Article References: Li, Z., Ning, J., Lin, C., Xiang, Y., Zhang, Y., Yuan, H., Yang, J., He, R., Yan, Z., & He, J. (2026). Development of pimobendan chewable tablets: pharmaceutical characterization and comparative pharmacokinetic evaluation in beagle dogs. BMC Veterinary Research. https://doi.org/10.1186/s12917-026-06031-4

Image Credits: AI Generated

DOI: 10.1186/s12917-026-06031-4

Keywords: pimobendan, chewable tablets, beagle dogs, pharmacokinetics, canine cardiology, veterinary pharmacology, dissolution testing, drug stability, Development, chewable, tablets, pharmaceutical

News Source: William Thompson. (November 9, 2026). Chewable Pimobendan Tablet Matches Commercial Formulation in Beagle Dog Study. Scienmag.

Tags: beagle dogscanine cardiologychewablechewable tabletsDevelopmentdissolution testingdrug stabilityPharmaceuticalPharmacokineticspimobendantabletsveterinary pharmacology
Share12Tweet7Share2ShareShareShare1

Related Posts

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

November 17, 2026
Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

November 17, 2026

Review finds disease prevention guidance prioritizes genetic risk over modifiable factors

November 17, 2026

Study Finds Only Sixteen Percent of Ethiopian Mothers Complete Continuum of Care

November 17, 2026

POPULAR NEWS

  • Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    29 shares
    Share 12 Tweet 7
  • Quality Improvement Project Raises Pre-Antibiotic Microbiological Analysis Rate to 79.2 Percent

    29 shares
    Share 12 Tweet 7
  • LLM-Driven Social Simulations Face Significant Epistemic Validity Challenges

    29 shares
    Share 12 Tweet 7
  • Veterinary Brucellosis Testing Requires Validated Decision Rules Across Animal Populations

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

Review finds disease prevention guidance prioritizes genetic risk over modifiable factors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.